PET/MR Evaluation of Regression Grading After Neoadjuvant Therapy for Rectal Cancer - Trial NCT06318234
Access comprehensive clinical trial information for NCT06318234 through Pure Global AI's free database. This phase not specified trial is sponsored by Xiao Chen and is currently Recruiting. The study focuses on Rectal Cancer. Target enrollment is 32 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Xiao Chen
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Timeline & Enrollment
N/A
Jan 01, 2024
Dec 31, 2025
Primary Outcome
Evaluation efficacy of tumor regression level
Summary
This project aims to evaluate the role of 18F-FAPI combined with 18F-FDG PET/MRI imaging in
 quantitatively and accurately evaluating the grading of rectal cancer after SCRT neoadjuvant
 therapy in patients with advanced rectal cancer as the research object, with postoperative
 histopathological analysis as the reference index, and to assess the ability of patients to
 achieve pCR. A diagnostic model and evaluation system will also be constructed.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06318234
Non-Device Trial